Table 1.
Major criteria |
• Exposure to an external stimulus (infection, vaccine, silicone, adjuvant) prior to clinical manifestations |
• The appearance of ‘typical’ clinical manifestations: |
- Myalgia, Myositis or muscle weakness |
- Arthralgia and/or arthritis |
- Chronic fatigue, un-refreshing sleep or sleep disturbances |
- Neurological manifestations (especially associated with demyelination) |
- Cognitive impairment, memory loss |
- Pyrexia, dry mouth |
• Removal of inciting agent induces improvement |
• Typical biopsy of involved organs |
Minor criteria |
• The appearance of autoantibodies or antibodies directed at the suspected adjuvant |
• Other clinical manifestations (i.e. irritable bowel syndrome) |
• Specific HLA (i.e. HLA DRB1, HLA DQB1) |
• Evolvement of an autoimmune disease (i.e. multiple sclerosis, systemic sclerosis) |
ASIA autoimmune/inflammatory syndrome induced by adjuvants